Cellectar Biosciences
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Campus Dr Ste 207, Florham Park, New...Phone Number
(608) 441-8120Website
www.cellectar.comRevenue
-Stock Symbol
CLRBIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
2
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.Explore more
Cellectar Biosciences Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellectar Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Cellectar Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cellectar Biosciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Cellectar Biosciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Cellectar Biosciences
Funding: Get notified immidiatlly once Cellectar Biosciences has new funding data
Check out if Cellectar Biosciences is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Cellectar Biosciences had a recent Job posting/layoffs
Check if Cellectar Biosciences has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Cellectar Biosciences
Compare insights from companies similar to Cellectar Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellectar Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cellectar Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cellectar Biosciences.
Cellectar Biosciences financials insights
Gather financial insights about Cellectar Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$9.2M
2017
Stock Offering
$7.8M
2018
Stock Offering
$16.6M
2019
Stock Offering
$10M
2020
Debt
$150K
2023
Share Placement
$102.9M
2025
Stock/Share Issuance
$2.5M
Cellectar Biosciences Tech Stack
A closer look at the technologies used by Cellectar Biosciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Spending/Investment, Finance, Financial Operations
Cellectar Biosciences News & Media
Cellectar Biosciences secures $140M financing, reports 79% response rate in WaM trial
Cellectar Biosciences reported cash and cash equivalents of $34.0 million as of 30 June 2026, up from $13.2 million at the end of 2025. In May, the company completed an oversubscribed financing, securing $35 million upfront and up to $105 million tied to future milestones. The company reported a net loss of $6.9 million for Q2 2026, compared to $5.4 million in the same period last year. R&D expenses nearly doubled to $4.6 million from $2.4Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ...
Company reports 79.2% major response rate in high-risk WM patients and secures up to $140 million to support NDA submission and pipeline expansion.Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call August 13, 2026 8:30 AM EDTCompany ParticipantsJames Caruso - President, CEO & DirectorChad...Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cellectar Biosciences
Sign Up For FreeTo access detailed company insights
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study fo... Read More
